dm+d

Unassigned

New Medicines

HIV infection - pre-exposure prophylaxis

Information

New molecular entity
Merck Sharp & Dohme (MSD)
Merck & Co (name used in US for MSD)

Development and Regulatory status

None
None
Phase III Clinical Trials

Category

A long-acting NRTTI (nucleoside reverse transcriptase translocation inhibitor)
In 2018, 103,800 people in were living with HIV (UK), ~96,000 of whom were diagnosed. Of the 97% on treatment, 3% fail to achieve viral suppression which indicates multi-drug resistance [1].
HIV infection - pre-exposure prophylaxis
Oral